Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

12th World Cancer Conference

London, UK

Abdullahi Mukhtar

Abdullahi Mukhtar

Cardiff University, UK

Title: Identifi cation and targeting of ‘spheroid’ forming cells in human malignant melanoma

Biography

Biography: Abdullahi Mukhtar

Abstract

Metastatic malignant melanoma (MM) is a therapy resistant tumour with conventional chemotherapy having little or no impact on survival. Th e median 1-year and 5-year survivals are 41% and 5% respectively. Th ere exist two classes of licensed biological drugs, B-Raf inhibitors and immune checkpoint inhibitors for those with inoperable diseases. However, there are issues of eligibility (only 50% of patients for B-Raf inhibitors, even then recurrence is inevitable), primary resistance or problem of toxicity (70-85% of patients fail to respond or cannot tolerate immune checkpoint inhibitors). Th erefore, there is an unmet clinical need for new therapies in treating metastatic melanoma. Melanoma Cancer stem cells were shown to be responsible for the resistance of MM to therapies and were characterized using certain cell surface proteins (ABCB5, CD133, CD271 and CD20). Among these, CD20 is potentially
targetable. We hypothesized that melanoma spheres facilitate hierarchical growth, including cancer stem cell markers and will recreate treatment responses. Seven (7) human melanoma cell lines were interrogated for sphere formation in 3D culture conditions and the expression of CD20 by fl ow Cytometric analysis. 6 of 7 cell lines formed spheres under non-adherent culture conditions, with reproducible sphere forming effi ciency. 50% of them expressed the human CD20 antigen, in 1 to 15% of cells with demonstrable
treatment response. Melanoma ‘spheroids’ are enriched with CD20 expressing cells and could be of therapeutic target in MM.